In this paper, we focused on the next generation sequencing gene panels and did not consider routine tumor molecular profiling that may involve multiple assessments, each of which targets a single gene or type of mutation (e.g. HER2, BRCA1, BRCA2 in breast cancer, and EGFR, HER2, KRAS, and ALK in lung cancer). This evidence concerns the gene ALK and breast carcinoma.